Open AccessIs Transcatheter Aortic Valve Replacement Better Than Surgical Aortic Valve Replacement in Patients With Chronic Obstructive Pulmonary Disease? A Nationwide Inpatient Sample Analysis
Author(s) -
Ando Tomo,
Adegbala Oluwole,
Akintoye Emmanuel,
Ashraf Said,
Pahuja Mohit,
Briasoulis Alexandros,
Takagi Hisato,
Grines Cindy L.,
Afonso Luis,
Schreiber Theodore
Publication year - 2018
Publication title -
journal of the american heart association
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.494
H-Index - 85
ISSN - 2047-9980
DOI - 10.1161/jaha.117.008408
Subject(s) - medicine , aortic valve replacement , copd , cardiology , odds ratio , valve replacement , myocardial infarction , mechanical ventilation , respiratory failure , surgery , stenosis
Background Chronic obstructive pulmonary disease ( COPD ) patients are at increased risk of respiratory related complications after cardiac surgery. It is unclear whether transcatheter aortic valve replacement ( TAVR ) or surgical aortic valve replacement ( SAVR ) results in favorable outcomes among COPD patients. Methods and Results Patients were identified from the Nationwide Inpatient Sample database from 2011 to 2014. Patients with age ≥60, COPD , and either went transarterial TAVR or SAVR were included in the analysis. A 1:1 propensity‐matched cohort was created to examine the outcomes. A matched pair of 1210 TAVR and 1208 SAVR patients was identified. Respiratory‐related complications such as tracheostomy (0.8% versus 5.8%; odds ratio [ OR ], 0.14; P <0.001), acute respiratory failure (16.4% versus 23.7%; OR , 0.63; P =0.002), reintubation (6.5% versus 10.0%; OR , 0.49; P <0.001), and pneumonia (4.5% versus 10.1%; OR , 0.41; P <0.001) were significantly less frequent with TAVR versus SAVR . Use of noninvasive mechanical ventilation was similar between TAVR and SAVR (4.1% versus 4.8%; OR , 0.84; P =0.41). Non‐respiratory‐related complications, such as in‐hospital mortality (3.3% versus 4.2%; OR , 0.64; P =0.035), bleeding requiring transfusion (9.9% versus 21.7%; OR , 0.38; P <0.001), acute kidney injury (17.7% versus 25.3%; OR , 0.63; P <0.001), and acute myocardial infarction (2.4% versus 8.4%; OR , 0.19; P <0.001), were significantly less frequent with TAVR than SAVR . Cost ($56 099 versus $63 146; P <0.001) and hospital stay (mean, 7.7 versus 13.0 days; P <0.001) were also more favorable with TAVR than SAVR . Conclusions TAVR portended significantly fewer respiratory‐related complications compared with SAVR in COPD patients. TAVR may be a preferable mode of aortic valve replacement in COPD patients.